Abstract

In order to study the clinical efficacy of fluorouracil administered as a prodrug tegafur in combination with gimeracil and oteracil potassium (S-1) in the postoperative treatment of gastric cancer, in this study, 308 patients with clinically diagnosed gastric cancer and radical gastrectomy were followed up for data collection. The 308 patients were divided into treatment group and control group, and treated according to the experimental design. The data obtained was analysed, subjected to Χ2 test using SPSS20.0 software and the survival rate was calculated by Kaplan-Meier. The median was used to represent the survival time. The single factor analysis was performed by log-rank test. Multiple-factor analysis was performed using Cox analysis. Finally, the adverse reactions of patients with oral administration of S-1 were counted, and the clinical efficacy of the S-1 in the radical resection of gastric cancer was evaluated. The results showed that the median progress free survival of the treatment group and the control group were 7.7 and 5.4 months, respectively, and the median overall survival was 12.1 and 10.0 months, respectively (P>0.05). Adverse reactions were mainly manifested in hand-foot syndrome, gastrointestinal symptoms, bone marrow transplantation and other systemic symptoms. The study appeared to be of great significance in selecting treatment options for prolongation of survival time in patients after radical gastrectomy.